In ES-NSCLC, they reported a prevalence of EGFR actionable alterations equal to 16.1%, KRAS 41.7%, BRAF p.(V600E) 1.5%, MET exon 14 skipping alterations 3.1%, ALK rearrangements 1.8%, RET 1.1%, ROS1 0.6%, and zero NTRK-positive cases. This evidence concerns the gene MET and non-small cell lung carcinoma.